A new recommendation

PBAC recommends listing of adalimumab biosimilar The PBAC has recommended the Authority Required listing of adalimumab (Yuflyma) in the form of 40 mg in 0.4 mL pre-filled syringe and pre-filled pen as a biosimilar brand of Humira. Celltrion Healthcare Australia requested the new PBS listing of the adalimumab biosimilar under the same conditions as its

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Pharmacy’s billion dollar boom
Next Legal cannabis use on the rise